Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Is guselkumab off patent in u s?
Alogliptin benz cost?
Prolia and osteonecrosis?
Xenazine current manufacturer 2025?
Excipients list used in dexamethasone creams?

Can you provide the exact date of apotex's ruxolitinib anda filing in the us?

See the DrugPatentWatch profile for ruxolitinib

According to DrugPatentWatch.com, Apotex's Ruxolitinib ANDA filing in the US was submitted on March 18, 2021 [1]. Ruxolitinib is an oral Janus kinase (JAK) inhibitor used in the treatment of myelofibrosis [2].

Apotex is a Canadian pharmaceutical company that develops and manufactures generic versions of brand-name drugs, filing Abbreviated New Drug Applications (ANDAs) to gain FDA approval for generic versions of these products.

It's worth noting that the FDA's approval or rejection of this ANDA filing is not publicly known at this time.

Sources:

[1] DrugPatentWatch.com
[2] Wikipedia: Ruxolitinib



Other Questions About Ruxolitinib :

drugpatentwatch.com. (2023). ruxolitinib patent expiration date Is concurrent use of steroids ruxolitinib safe? What conditions does apotex's ruxolitinib treat? Ruxolitinib in canada loss of exclusitivity? Ruxolitinib pronounce? In head to head trials does ruxolitinib's efficacy outshine azacitidine s? Can you provide the approval date for apotex's ruxolitinib?